Proschak E
Proschak E
Junior Professor in Drug Design
確認したメール アドレス:
PocketPicker: analysis of ligand binding-sites with shape descriptors
M Weisel, E Proschak, G Schneider
Chemistry Central Journal 1 (1), 7, 2007
The holistic integration of virtual screening in drug discovery
Y Tanrikulu, B Krüger, E Proschak
Drug Discovery Today 18 (7-8), 358-364, 2013
DOGS: reaction-driven de novo design of bioactive compounds
M Hartenfeller, H Zettl, M Walter, M Rupp, F Reisen, E Proschak, ...
PLoS computational biology 8 (2), 2012
Inhibitors of the arachidonic acid cascade: interfering with multiple pathways
K Meirer, D Steinhilber, E Proschak
Basic & clinical pharmacology & toxicology 114 (1), 83-91, 2014
Voyages to the (un) known: adaptive design of bioactive compounds
G Schneider, M Hartenfeller, M Reutlinger, Y Tanrikulu, E Proschak, ...
Trends in biotechnology 27 (1), 18-26, 2009
Approved drugs containing thiols as inhibitors of metallo-β-lactamases: strategy to combat multidrug-resistant bacteria
FM Klingler, TA Wichelhaus, D Frank, J Cuesta-Bernal, J El-Delik, ...
Journal of medicinal chemistry 58 (8), 3626-3630, 2015
Kernel approach to molecular similarity based on iterative graph similarity
M Rupp, E Proschak, G Schneider
Journal of chemical information and modeling 47 (6), 2280-2286, 2007
Computational tools for polypharmacology and repurposing
J Achenbach, P Tiikkainen, L Franke, E Proschak
Future medicinal chemistry 3 (8), 961-968, 2011
2, 4-Diaminopyrimidines as histamine H4 receptor ligands—Scaffold optimization and pharmacological characterization
K Sander, T Kottke, Y Tanrikulu, E Proschak, L Weizel, EH Schneider, ...
Bioorganic & medicinal chemistry 17 (20), 7186-7196, 2009
Concept of Combinatorial De Novo Design of Drug‐like Molecules by Particle Swarm Optimization
M Hartenfeller, E Proschak, A Schüller, G Schneider
Chemical biology & drug design 72 (1), 16-26, 2008
Form follows function: shape analysis of protein cavities for receptor‐based drug design
M Weisel, E Proschak, JM Kriegl, G Schneider
Proteomics 9 (2), 451-459, 2009
Scaffold hopping by “fuzzy” pharmacophores and its application to RNA targets
Y Tanrikulu, M Nietert, U Scheffer, E Proschak, K Grabowski, P Schneider, ...
ChemBioChem 8 (16), 1932-1936, 2007
Polypharmacology by design: a medicinal chemist’s perspective on multitargeting compounds
E Proschak, H Stark, D Merk
Journal of medicinal chemistry 62 (2), 420-444, 2018
SAR-study on a new class of imidazo [1, 2-a] pyridine-based inhibitors of 5-lipoxygenase
M Hieke, CB Rödl, JM Wisniewska, E la Buscató, H Stark, ...
Bioorganic & medicinal chemistry letters 22 (5), 1969-1975, 2012
Homology Model Adjustment and Ligand Screening with a Pseudoreceptor of the Human Histamine H4 Receptor
Y Tanrikulu, E Proschak, T Werner, T Geppert, N Todoroff, A Klenner, ...
ChemMedChem: Chemistry Enabling Drug Discovery 4 (5), 820-827, 2009
Structure–Activity Relationship of Nonacidic Quinazolinone Inhibitors of Human Microsomal Prostaglandin Synthase 1 (mPGES 1)
F Rörsch, E Buscató, K Deckmann, G Schneider, M Schubert-Zsilavecz, ...
Journal of medicinal chemistry 55 (8), 3792-3803, 2012
Molecular query language (mql) a context-free grammar for substructure matching
E Proschak, JK Wegner, A Schüller, G Schneider, U Fechner
Journal of chemical information and modeling 47 (2), 295-301, 2007
Lipoxin and resolvin biosynthesis is dependent on 5-lipoxygenase activating protein
C Lehmann, J Homann, AK Ball, R Blöcher, TK Kleinschmidt, ...
The FASEB Journal 29 (12), 5029-5043, 2015
Shapelets: Possibilities and limitations of shape‐based virtual screening
E Proschak, M Rupp, S Derksen, G Schneider
Journal of computational chemistry 29 (1), 108-114, 2008
Opportunities and challenges for fatty acid mimetics in drug discovery
E Proschak, P Heitel, L Kalinowsky, D Merk
Journal of medicinal chemistry 60 (13), 5235-5266, 2017
論文 1–20